Clinical-stage biotechnology company
Appears in 1 story · Last updated Nov 22, 2026
Sponsor of the Phase 1 trial of PT0253
PAQ Therapeutics released the first human data for PT0253, a drug that destroys the mutant KRAS G12D protein rather than blocking it. Across 44 patients with advanced solid tumors, weekly infusions caused no dose-limiting toxicity at any dose from 10 to 750 milligrams, and tumors shrank in colorectal and pancreatic cancer.
Updated 55 minutes ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?